Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 474

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?

Felson, David T., Anderson, Jennifer J., Lange, Mary L. M., Wells, George, LaValley, Michael P.·1998·Arthritis & Rheumatism
DOI 10.1002/1529-0131(199809)41:9
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine whether the initiation of corticosteroids or other types of therapy affects the development of scleroderma renal crisis (SRC). METHODS: Using a case-control study, 110 patients with systemic sclerosis who developed SRC between 1981 and 1993 were closely matched with controls on sex, race, age, disease duration, skin score, levels of creatine phosphokinase, and presence of tendon friction rubs. Corticosteroid use was determined prior to the onset of SRC in cases or prior to the first visit in controls. Cases were compared with matched controls using McNemar's matched-pair analysis and conditional logistic regression analysis. The effects of other drugs, including D-penicillamine, nonsteroidal antiinflammatory drugs (NSAIDs), calcium channel blockers, and angiotensin-converting enzyme (ACE) inhibitors, were also evaluated. RESULTS: In the 6 months prior to SRC onset or to the first visit, high-dose corticosteroids (> or =15 mg/day prednisone or equivalent) were administered significantly more frequently in SRC patients (36%) than in the controls (12%) (McNemar's odds ratio 4.37, 95% confidence interval 2.03-9.43, P < 0.0001). New use of low-dose steroids, continuous use of any steroid dose, NSAIDs, calcium channel blockers, and ACE inhibitors were not associated with an increased risk of SRC. Antecedent D-penicillamine therapy may have been protective against the development of SRC in controls. CONCLUSION: This retrospective case-control study has shown a significant association between antecedent high-dose corticosteroid therapy and the development of SRC. These results should discourage the use of high-dose corticosteroids in patients with early diffuse scleroderma who are at increased risk of developing SRC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/1529-0131(199809)41:9<1564::aid-art6>3.0.co;2-m

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 18

  1. Felson, 1995, Arthritis Rheum, 38, 727, 10.1002/art.1780380602 · DOI · Paper page
  2. Felson, 1993, Arthritis Rheum, 36, 729, 10.1002/art.1780360601 · DOI · Paper page
  3. Pillemer, 1993, Arthritis Rheum, 40, 419, 10.1002/art.1780400305 · doi:10.1002/art.1780400305
  4. Moreland, 1997, N Engl J Med, 337, 141, 10.1056/NEJM199707173370301 · DOI · Paper page
  5. Van den Borne, 1996, Scand J Rheumatol, 25, 307, 10.3109/03009749609104063 · DOI
  6. Paulus, 1990, Arthritis Rheum, 33, 477, 10.1002/art.1780330403 · DOI · Paper page
  7. O'Dell, 1997, Arthritis Rheum, 40, 842, 10.1002/art.1780400510 · DOI · Paper page
  8. Ferracciolo, 1997, Arthritis Rheum, 40, s219
  9. Bombardier, 1982, J Rheumatol, 9, 753
  10. Arnett, 1988, Arthritis Rheum, 31, 315, 10.1002/art.1780310302 · DOI · Paper page
  11. Williams, 1985, Arthritis Rheum, 28, 721, 10.1002/art.1780280702 · DOI · Paper page
  12. Williams, 1983, Arthritis Rheum, 26, 581, 10.1002/art.1780260502 · DOI
  13. Ward, 1983, Arthritis Rheum, 26, 1303, 10.1002/art.1780261102 · DOI · Paper page
  14. Weinblatt, 1990, Arthritis Rheum, 33, 330, 10.1002/art.1780330305 · doi:10.1002/art.1780330305
  15. Tugwell, 1995, N Engl J Med, 333, 137, 10.1056/NEJM199507203330301 · DOI · Paper page
  16. Felson, 1990, Arthritis Rheum, 33, 1449, 10.1002/art.1780331001 · DOI · Paper page
  17. Felson, 1992, Arthritis Rheum, 35, 1117, 10.1002/art.1780351003 · DOI · Paper page
  18. The arcsine transformation and the effect size index. In: Statistical power analysis for the behavioral science. 2nd ed. Hillsdale (NJ): Lawrence Erlbaum Associates; 1988. p. 180-5.

Cited by

See all 474

Metadata

Authors
Felson, D. T., Anderson, J. J., Lange, M. L. M., Wells, G., & LaValley, M. P.
Venue
Arthritis & Rheumatism
Publisher
Wiley
Published
1998-09
Volume
41
Issue
9
Pages
1564-1570
ISSN
  • 0004-3591 (ISSN-L)
  • 1529-0131
DOI
10.1002/1529-0131(199809)41:9
OpenAlex
W2159860060
Cited by
474
References
13
FWCI
5.87
Type
journal article
Language
en
Open access
closed
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 6209 d)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? https://app.cochat.ai/papers/10.1002/1529-0131(199809)41:9
The paper
Felson, D. T., Anderson, J. J., Lange, M. L. M., Wells, G., & LaValley, M. P. (1998). Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis & Rheumatism. https://doi.org/10.1002/1529-0131(199809)41%3A9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.